Evidence map›Paper›PMID 37438422›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2024

Exploring the role of mu opioid receptors in the therapeutic potential and abuse liability of (S)-ketamine.

Marjorie R Levinstein, Michael Michaelides

Abstract readNews
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Structural basis of opioid receptor activation by PCP and ketamine.Nature structural & molecular biology · 2026
    Article
  2. Esketamine in depression: putative biomarkers from clinical research.European archives of psychiatry and clinical neuroscience · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marjorie R LevinsteinBiobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, 21224, USA. Marjorie.levinstein@nih.gov.ORCID 0000-0003-4360-1503
Michael MichaelidesBiobehavioral Imaging and Molecular Neuropsychopharmacology Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, 21224, USA. Mike.michaelides@nih.gov.ORCID 0000-0003-0398-4917

Funding

Biobehavioral Imaging and Molecular Neuropsychopharmacology of Substance Abuse MechanismsZIADA000069 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI MICHAELIDES, MICHAEL · 2016 to 2025
$18.9M
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) ZIA000069
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

KetamineAnalgesics, OpioidHumansPainReceptors, Opioid, muAnalgesics, OpioidKetamineReceptors, Opioid, mu

Identifiers

PMID37438422
PMCPMC10700302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.